期刊文献+

Nuclear morphometry, nucleomics and prostate cancer progression 被引量:2

核形态学,核子学与前列腺癌的研究进展
下载PDF
导出
摘要 Prostate cancer (PCa) results from a multistep process. This process includes initiation, which occurs through various aging events and multiple insults (such as chronic infection, inflammation and genetic instability through reactive oxygen species causing DNA double-strand breaks), followed by a multistep process of progression. These steps include several genetic and epigenetic alterations, as well as alterations to the chromatin structure, which occur in response to the carcinogenic stress-related events that sustain proliferative signaling. Events such as evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis are readily observed. In addition, in conjunction with these critical drivers of carcinogenesis, other factors related to the etiopathogenesis of PCa, involving energy metabolism and evasion of the immune surveillance system, appear to be involved. In addition, when cancer spread and metastasis occur, the 'tumor microenvironment' in the bone of PCa patients may provide a way to sustain dormancy or senescence and eventually establish a 'seed and soil' site where PCa proliferation and growth may occur over time. When PCa is initiated and progression ensues, significant alterations in nuclear size, shape and heterochromatin (DNA transcription) organization are found, and key nuclear transcriptional and structural proteins, as well as multiple nuclear bodies can lead to precancerous and malignant changes. These series of cellular and tissue-related malignancy-associated events can be quantified to assess disease progression and management. Prostate cancer (PCa) results from a multistep process. This process includes initiation, which occurs through various aging events and multiple insults (such as chronic infection, inflammation and genetic instability through reactive oxygen species causing DNA double-strand breaks), followed by a multistep process of progression. These steps include several genetic and epigenetic alterations, as well as alterations to the chromatin structure, which occur in response to the carcinogenic stress-related events that sustain proliferative signaling. Events such as evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis are readily observed. In addition, in conjunction with these critical drivers of carcinogenesis, other factors related to the etiopathogenesis of PCa, involving energy metabolism and evasion of the immune surveillance system, appear to be involved. In addition, when cancer spread and metastasis occur, the 'tumor microenvironment' in the bone of PCa patients may provide a way to sustain dormancy or senescence and eventually establish a 'seed and soil' site where PCa proliferation and growth may occur over time. When PCa is initiated and progression ensues, significant alterations in nuclear size, shape and heterochromatin (DNA transcription) organization are found, and key nuclear transcriptional and structural proteins, as well as multiple nuclear bodies can lead to precancerous and malignant changes. These series of cellular and tissue-related malignancy-associated events can be quantified to assess disease progression and management.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2012年第3期375-384,I0005,共11页 亚洲男性学杂志(英文版)
关键词 active surveillance cancer metastasis cancer progression digital image analysis molecular biomarkers morphologicalbiomarkers nuclear morphometry nuclear proteins and nuclear structure prostate cancer active surveillance, cancer metastasis, cancer progression, digital image analysis, molecular biomarkers, morphologicalbiomarkers, nuclear morphometry, nuclear proteins and nuclear structure, prostate cancer
  • 相关文献

参考文献102

  • 1Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA. CA Cancer J Cfin 2010; 60: 277-300.
  • 2Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90.
  • 3Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78.
  • 4Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Onco1201O; 7: 394-400.
  • 5Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol2009; 55: 1321-30.
  • 6Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101.
  • 7Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. TJ Urol2003; 169: 517-23.
  • 8Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
  • 9Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev2004; 4: 677-87.
  • 10Bartova E, Krejci J, Harnicarova A, Galiova G, Kozubek S. Histone modifications and nuclear architecture: a review. J Histochem Cytochem 2008; 56: 711-2l.

同被引文献9

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部